Compare Cassava Sciences Inc (FLNA) vs Invesco NASDAQ 100 ETF (QQQM) Price & Performance

FLNA trades at $0.8168 with minimal daily movement (+0.13%). The stock shows bearish technical signals with negative moving averages but has beaten earnings expectations for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam enables Phase 2a epilepsy trials, providing potential catalyst. However, the company reports zero revenue, negative EBITDA of -$95.19M, and concerning cash flow trends with net cash outflow of -$33.07M in 2025.

While analyst consensus is strongly bullish (67% buy ratings), fundamental weaknesses including negative profitability metrics and cash burn present significant risks. The FDA approval provides near-term optimism for the epilepsy drug pipeline, but execution risk remains high given the company's financial position and lack of current revenue streams.

QQQM trades at $309.39, down 0.84% on the day, with a bullish technical signal from moving averages while oscillators remain neutral. The ETF's lower 0.15% expense ratio compared to QQQ's 0.18% provides a cost advantage, though trading spreads can impact returns. Recent institutional buying includes QRG Capital Management increasing its position by 207.5% during Q2 2026 (SEC filing, September 28, 2026).

The outlook remains positive given the Nasdaq-100's exposure to technology growth stocks, though concentration risk in top holdings and potential tax complications with covered-call alternatives like QQQI warrant caution. Market leadership from small-cap stocks within the index suggests continued momentum, but investors should monitor valuation levels given the current price near resistance at $311.